These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8695283)

  • 1. Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma.
    Tessier MH; Pandolfino MC; Jotereau F; Boudart D; Litoux P; Dréno B
    Eur J Cancer; 1996 Apr; 32A(4):735-6. PubMed ID: 8695283
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
    J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes.
    Hum Gene Ther; 1992 Apr; 3(2):167-77. PubMed ID: 1391037
    [No Abstract]   [Full Text] [Related]  

  • 5. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
    Möller P; Wittig B; Schadendorf D
    Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
    Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
    Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Legha SS
    J Natl Cancer Inst; 1995 Feb; 87(4):319. PubMed ID: 7707427
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
    Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
    Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.
    Håkansson A; Gustafsson B; Krysander L; Hjelmqvist B; Rettrup B; Håkansson L
    Br J Cancer; 2001 Dec; 85(12):1871-7. PubMed ID: 11747328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
    Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
    Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
    Itoh K; Balch CM; Murray JL; Parkinson DR; Markowitz AB; Talpaz M; Lee K; Zukiwski AA; Ross MI; Legha SS
    In Vivo; 1991; 5(6):647-53. PubMed ID: 1810451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
    Pilon-Thomas S; Kuhn L; Ellwanger S; Janssen W; Royster E; Marzban S; Kudchadkar R; Zager J; Gibney G; Sondak VK; Weber J; Mulé JJ; Sarnaik AA
    J Immunother; 2012 Oct; 35(8):615-20. PubMed ID: 22996367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.